Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the stock trades at $4.68, well below JP Morgan’s price target of $11, indicating a potential upside of more than 135%. This move is critical for investors who may want to position themselves in a company that is increasingly being recognized for its growth potential in the biopharmaceutical sector.
Recent Price Action
In the past week, RXRX’s stock experienced a solid uptick, closing at $4.68 after an increase of $0.48, or approximately 11.43%. With a market capitalization of about $1.88 billion, the stock has demonstrated remarkable volatility, evidenced by a weekly change averaging 5.6% and a monthly volatility clocking in at 6.57%. Over the last 52 weeks, the stock has oscillated between a low of $23.48 and a high of $4.68, underscoring the stock’s challenging journey amidst broader market fluctuations. With trading volume reaching over 64 million shares on certain days this week, far surpassing its average of about 43 million, investor sentiment appears to be shifting positively toward the stock.
Short- and Long-Term Performance
Over a 30-day timeframe, Recursion Pharmaceuticals has shown a recovery with a notable performance of 13.59%. In stark contrast, the stock has faced difficulties over the past 90 days, recording a decline of 5.07%. The yearly performance tells a more challenging story, with the stock decreasing by approximately 32.95%, largely reflecting the turbulence within the biotechnology sector and pressures from macroeconomic factors. Investors have witnessed a significant shift in market dynamics, and RXRX is now in the spotlight amid these changes.
Earnings and Financials
On November 5, 2025, Recursion Pharmaceuticals reported an EPS (earnings per share) of -$0.36, slightly beating analyst estimates of -$0.38. However, the stock’s surprise factor of -4.48% signals ongoing volatility regarding its earnings predictability. This marks an improvement from the previous quarter, where it posted an EPS of -$0.41 against an estimate of -$0.35, resulting in a positive surprise of 17.14%. Although these earnings are in the negative territory, they reflect the company’s efforts towards stabilizing its financial outlook, which can be a turning point for potential investors.
Analyst / Consensus View
The consensus surrounding Recursion Pharmaceuticals has taken a positive turn with JP Morgan’s recent shift to an “Overweight” rating. Currently, the consensus consists of only one rating, indicating a singular bullish outlook, with an average price target set firmly at $11, the same as the high and low price targets indicated. This single “Buy” rating, devoid of “Hold” or “Sell” suggestions, illustrates an overall confidence in the company’s recovery trajectory and future prospects among analysts.
Stock Grading and Fundamental View
Recursion Pharmaceuticals holds a Stocks Telegraph Grade of 26, suggesting that the company possesses certain strengths, although there may be areas for improvement. This score incorporates various financial and market metrics, indicating that while the company is navigating through a delicate phase, its fundamentals could still have room for growth. Investors are advised to undertake careful consideration of the inherent risks amidst a potential upswing in performance.
Conclusion
For long-term growth investors, Recursion Pharmaceuticals (RXRX) appears to be an intriguing option, particularly in light of JP Morgan’s recent upgrade. However, prospective investors should be wary of the inherent risks associated with investing in a company that is still grappling with losses and a volatile market environment. The positive sentiment from analysts, along with an attractive price-to-target ratio, makes RXRX worth monitoring. Nonetheless, investors must remain cognizant of the biopharmaceutical’s unpredictable trajectory as it seeks to solidify its standing in an increasingly competitive landscape.